Investment
Features
FeesSafety
Academy
More
Pluang+

Marvel Biosciences' MB-204 shows positive preclinical results reversing Fragile X symptoms in mice.

Market News
05 Aug 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Marvel Biosciences announced that its lead drug candidate, MB-204, demonstrated significant improvements in behavioral and cognitive functions in a Fragile X mouse model during preclinical trials. The drug showed dose-dependent efficacy and durable effects even after treatment stopped, supporting its potential for treating Fragile X syndrome and other autism spectrum disorders. These results add to previous positive findings in Rett syndrome and other ASD models, strengthening the case for advancing MB-204 to clinical trials. The company is also awaiting results from another related preclinical study.

More News (MRVL)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App